iN-KEY iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY
- Coordinator
- Banc De Sang I Teixits, Spain
- Runs
- 1 October 2026 to 30 September 2031
- Status
- Running
- EU funding
- €10.0m
- Total cost
- €10.0m
- Partners
- 13 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287295
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite the transformative potential of CAR-T cell therapies, their widespread adoption is hindered by significant barriers, including prohibitive costs, severe toxicities, logistical challenges in manufacturing, and limited efficacy. The iN-KEY consortium aims to overcome these challenges by developing and clinically validating a next-generation, ""off-the-shelf"" immunotherapy platform for the treatment of Multiple Myeloma (MM).
At the heart of this project is a disruptive platform based on engineered induced Pluripotent Stem Cells (iPSCs). This platform integrates several key innovations: 1) Highly immunocompatible, haplo-matched iPSC lines for broad allogeneic use
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Banc De Sang I Teixits | Barcelona | Spain | Coordinator |
| Myeloma Patients Europe Aisbl | Bruxelles | Belgium | Participant |
| Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel | Langen | Germany | Participant |
| Catalent Dusseldorf GmbH | Langenfeld | Germany | Participant |
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Avanther Therapeutics SL | Madrid | Spain | Participant |
| Fundacio Institut D'investigacio Biomedica De Bellvitge | L'Hospitalet De Llobregat | Spain | Third party |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii | Madrid | Spain | Participant |
| Institut Catala D'oncologia | Hospitalet de Llobregat | Spain | Participant |
| Stab Therapeutics SL | Madrid | Spain | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Eatris Eric | Amsterdam | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI